CERS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CERS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Cerus's Capital Expenditure for the three months ended in Mar. 2024 was $-1.10 Mil. Its Revenue for the three months ended in Mar. 2024 was $38.37 Mil.
Hence, Cerus's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.03.
The historical data trend for Cerus's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Revenue | Get a 7-Day Free Trial | 0.12 | 0.02 | 0.01 | 0.01 | 0.03 |
Cerus Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Capex-to-Revenue | Get a 7-Day Free Trial | 0.05 | 0.01 | 0.07 | - | 0.03 |
For the Medical Devices subindustry, Cerus's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cerus's Capex-to-Revenue falls into.
Cerus's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-4.597) | / | 156.367 | |
= | 0.03 |
Cerus's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-1.099) | / | 38.365 | |
= | 0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (NAS:CERS) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of Cerus's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Bjerkholt | director | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Ann Lucena | director | C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Gail Schulze | director | 3451 WELLS ROAD, MALVERN PA 19355 |
Laurence M Corash | director | C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520 |
William Mariner Greenman | officer: President, Cerus Europe | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Chrystal Menard | officer: Chief Legal Officer | C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520 |
Kevin Dennis Green | officer: Chief Accounting Officer | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Richard J Benjamin | officer: Chief Medical Officer | 15 WHITE PINE ROAD, NEWTON MA 02464 |
Vivek K Jayaraman | officer: Chief Commercial Officer | 3910 BRICKWAY BLVD, SANTA ROSA CA 95403 |
Hua Shan | director | C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520 |
Carol Moore | officer: SR. V.P. Regulatory, Clinical | C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520 |
Timothy B Anderson | director | C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015 |
Timothy L. Moore | director | C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404 |
Frank Witney | director | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
From GuruFocus
By Business Wire Business Wire • 07-21-2022
By Business Wire • 11-03-2023
By Business Wire Business Wire • 06-05-2023
By Business Wire Business Wire • 04-20-2023
By Business Wire Business Wire • 02-07-2022
By Business Wire • 01-08-2024
By Business Wire Business Wire • 06-14-2023
By Business Wire Business Wire • 07-05-2022
By Business Wire Business Wire • 05-03-2022
By Business Wire Business Wire • 02-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.